Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9321434 | European Urology Supplements | 2005 | 6 Pages |
Abstract
LHRH agonists have been thought to achieve an almost 100% of response in the initial therapy. Several studies have shown that when using a more stringent definition of castration, treatment with current LHRH agonists does not achieve this goal. As a consequence, measurement of testosterone should regain attention for evaluating treatment response to LHRH agonists as well as for monitoring breakthroughs and acute-on-chronic responses.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
B. Tombal,